Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.

Olga L Gurvich1, Therese M Tuohy, Michael T Howard

  • 1Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA.

Annals of Neurology
|December 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

U7snRNA-mediated skipping of intron-derived pseudoexons restores full-length <i>DMD</i> expression in patient-derived cell lines.

Molecular therapy. Advances·2026
Same author

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD.

Annals of clinical and translational neurology·2026
Same author

Generation of an induced pluripotent stem cell line (NCHi026-A) from a patient with a partial deletion of exon 55 in the DMD gene.

Stem cell research·2026
Same author

Unraveling the spatial landscape of dystrophinopathies: a transcriptomic approach to Becker and Duchenne muscular dystrophies.

The Journal of pathology·2026
Same author

Gene x environment interaction analysis confirms genetic modifier effects on steroid efficacy via TGF-β pathway in Duchenne muscular dystrophy.

European journal of human genetics : EJHG·2026
Same author

ALT/CK Ratio as an Early Marker of Liver Injury After Gene Therapy in Duchenne Muscular Dystrophy.

Pediatrics·2026

Deep intronic mutations causing pseudoexon inclusion lead to Duchenne (DMD) and Becker muscular dystrophy. Antisense oligonucleotide therapy can skip these pseudoexons, restoring dystrophin protein expression.

Area of Science:

  • Genetics
  • Molecular Biology
  • Biochemistry

Background:

  • Duchenne (DMD) and Becker muscular dystrophy are degenerative muscle diseases caused by mutations in the DMD gene, encoding dystrophin.
  • Deep intronic mutations are increasingly identified, leading to altered splicing and pseudoexon inclusion in messenger RNA.
  • The correlation between splicing efficiency and clinical phenotype severity requires further investigation.

Observation:

  • Three pseudoexon insertion mutations were identified in dystrophinopathy patients.
  • Quantitative reverse transcription polymerase chain reaction confirmed mutation-induced splicing alterations.
  • Antisense oligonucleotide (AON) treatment was tested on cultured primary myoblasts with pseudoexon mutations.

Findings:

  • Variable pseudoexon inclusion levels correlated with dystrophinopathy phenotype severity in two patients.

Related Experiment Videos

  • AON treatment targeting pseudoexons successfully induced full-length dystrophin expression in DMD myoblasts.
  • Out-of-frame pseudoexons can cause both DMD and Becker muscular dystrophy, with phenotype severity linked to splicing efficiency.

    • Implications:

    • Antisense oligonucleotide (AON)-mediated pseudoexon skipping presents a viable therapeutic strategy for dystrophinopathies.
    • This approach holds potential for increasing wild-type dystrophin protein expression in affected individuals.
    • Understanding splicing efficiency is crucial for predicting disease severity and therapeutic outcomes in DMD and Becker muscular dystrophy.